Similarly, the sEH metabolite 19,20-DHDP has recently been identified as crucial mediator of diabetic retinopathy and treatment of mice with an sEH inhibitor caused a reduction of 19,20- Dihydroxydocosapentaenoic acid (19,20-DHDP) concentrations in the retina and a reduction of diabetic retinopathy in vivo (Hu et al., 2017). Here, EPHX2 is linked to diabetic retinopathy.